Literature DB >> 27737954

Time Until Emergence of HIV Test Reactivity Following Infection With HIV-1: Implications for Interpreting Test Results and Retesting After Exposure.

Kevin P Delaney1, Debra L Hanson1, Silvina Masciotra1, Steven F Ethridge1, Laura Wesolowski1, Sherry Michele Owen2.   

Abstract

BACKGROUND: Understanding the period of time between an exposure resulting in infection with human immunodeficiency virus (HIV) and when a test can reliably detect the presence of that infection, that is, the test window period, may benefit testing programs and clinicians in counseling patients about when the clinician and the patient can be confident a suspected exposure did not result in HIV infection.
METHODS: We evaluated the intervals between reactivity of the Aptima HIV-1 RNA test (Aptima) and 20 US Food and Drug Administration-approved HIV immunoassays using 222 longitudinally collected plasma specimens from HIV-1 seroconverters from the United States. Using interval-censored survival and binomial regression approaches a multi-model framework was implemented to estimate the relative emergence of test reactivity, referred to here as an inter-test reactivity interval (ITRI). We then combined ITRI results with simulated data for the eclipse period, the time between exposure and detection of HIV virus by Aptima, to estimate the window period for each test.
RESULTS: The estimated ITRIs were shorter with each new class of HIV tests, ranging from 5.9 to 24.8 days. The 99th percentiles of the window period probability distribution ranged from 44 days for laboratory screening tests that detect both antigen and antibody to 65 days for the Western blot test.
CONCLUSIONS: Our directly comparable estimates of the emergence of reactivity for 20 immunoassays are valuable to testing providers for interpreting negative HIV test results obtained shortly after exposure, and for counseling individuals on when to retest after an exposure. Published by Oxford University Press for the Infectious Diseases Society of America 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US.

Entities:  

Keywords:  HIV eclipse period; HIV immunoassays; RNA nucleic acid test; window period of infection

Mesh:

Substances:

Year:  2016        PMID: 27737954     DOI: 10.1093/cid/ciw666

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  30 in total

1.  Comparison of Detection Limits of Fourth- and Fifth-Generation Combination HIV Antigen-Antibody, p24 Antigen, and Viral Load Assays on Diverse HIV Isolates.

Authors:  Mars Stone; John Bainbridge; Ana M Sanchez; Sheila M Keating; Andrea Pappas; Wes Rountree; Chris Todd; Sonia Bakkour; Mark Manak; Sheila A Peel; Robert W Coombs; Eric M Ramos; M Kathleen Shriver; Paul Contestable; Sangeetha Vijaysri Nair; David H Wilson; Martin Stengelin; Gary Murphy; Indira Hewlett; Thomas N Denny; Michael P Busch
Journal:  J Clin Microbiol       Date:  2018-07-26       Impact factor: 5.948

2.  Short Communication: Heightened HIV Antibody Responses in Postpartum Women as Exemplified by Recent Infection Assays: Implications for Incidence Estimates.

Authors:  John W Hargrove; Cari van Schalkwyk; Jean H Humphrey; Kuda Mutasa; Robert Ntozini; Sherry Michele Owen; Silvina Masciotra; Bharat S Parekh; Yen T Duong; Trudy Dobbs; Peter H Kilmarx; Elizabeth Gonese
Journal:  AIDS Res Hum Retroviruses       Date:  2017-05-24       Impact factor: 2.205

Review 3.  Selecting an HIV Test: A Narrative Review for Clinicians and Researchers.

Authors:  Christopher B Hurt; Julie A E Nelson; Lisa B Hightow-Weidman; William C Miller
Journal:  Sex Transm Dis       Date:  2017-12       Impact factor: 2.830

4.  HIV antiretroviral therapy and prevention use in US blood donors: a new blood safety concern.

Authors:  Brian Custer; Claire Quiner; Richard Haaland; Amy Martin; Mars Stone; Rita Reik; Whitney R Steele; Debra Kessler; Phillip C Williamson; Steven A Anderson; Alan E Williams; Henry F Raymond; Willi McFarland; William T Robinson; Sara Glick; Kwa Sey; C David Melton; Simone A Glynn; Susan L Stramer; Michael P Busch
Journal:  Blood       Date:  2020-09-10       Impact factor: 22.113

5.  Field performance of the INSTI HIV-1/-2 antibody test in two South African antenatal clinics.

Authors:  Simnikiwe H Mayaphi; Desmond J Martin; Thomas C Quinn; Anton C Stoltz
Journal:  J Med Virol       Date:  2019-03-18       Impact factor: 2.327

6.  Performance evaluation of the MedMira reveal G4 LAB S/P and POC HIV antibody rapid screening tests using plasma and whole blood specimens.

Authors:  Rebecca Rossetti; Tara Smith; Wei Luo; Silvina Masciotra
Journal:  J Clin Virol       Date:  2020-04-11       Impact factor: 3.168

7.  A generalizable method for estimating duration of HIV infections using clinical testing history and HIV test results.

Authors:  Christopher D Pilcher; Travis C Porco; Shelley N Facente; Eduard Grebe; Kevin P Delaney; Silvina Masciotra; Reshma Kassanjee; Michael P Busch; Gary Murphy; S Michele Owen; Alex Welte
Journal:  AIDS       Date:  2019-06-01       Impact factor: 4.177

8.  Limited Knowledge and Lack of Screening for Acute HIV Infection at Primary Care Clinics in High-Prevalence Communities of New York City.

Authors:  Javier Lopez-Rios; Timothy Frasca; Marcia J Kindlon; Theresa M Exner; Andrea Norcini Pala; Milton L Wainberg; Yvette Calderon; Richard Cotroneo; Arismendi A Jiménez; Robert H Remien
Journal:  AIDS Behav       Date:  2019-10

9.  No Time to Delay! Fiebig Stages and Referral in Acute HIV infection: Seattle Primary Infection Program Experience.

Authors:  Joanne D Stekler; Kenneth Tapia; Janine Maenza; Claire E Stevens; George A Ure; Joshua D O'Neal; Aric Lane; James I Mullins; Robert W Coombs; Sarah Holte; Ann C Collier
Journal:  AIDS Res Hum Retroviruses       Date:  2018-06-13       Impact factor: 2.205

10.  Use of the Bio-Rad Geenius HIV-1/2 supplemental assay for the testing of oral fluids for the presence of HIV antibody.

Authors:  Maria Elma; Kathryn Krusel; Megan Crumpler; Nico Tavella; Ali Talan; Jonathon Rendina; Mark Pandori
Journal:  J Clin Virol       Date:  2020-05-06       Impact factor: 3.168

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.